Division of Nephrology, Department of Medicine, Ladoke Akintola University of Technology, P.O. Box 710, Ogbomoso, Osogbo, Nigeria,
Int Urol Nephrol. 2013 Oct;45(5):1289-300. doi: 10.1007/s11255-012-0376-9. Epub 2013 Jan 10.
To report the long-term outcome and complication profile of South African patients with proliferative lupus nephritis (PLN).
A retrospective review of 66 patients with biopsy-proven PLN [58 diffuse proliferative LN (Class IV) and 8 focal proliferative LN (Class III)] under our care from January 1995 to December 2009 was done.
Thirty-three (50 %) patients reached the composite end point of doubling of serum creatinine, end-stage renal disease (ESRD) or death. The 5-, 10- and 15-year cumulative event-free survival rates were 54, 34 and 27 %, respectively. Variables associated with the composite end point were simultaneous diagnosis of SLE and LN (p = 0.048); elevated serum creatinine at onset (p = 0.009); elevated systolic blood pressure (SBP) (p < 0.001) and elevated diastolic blood pressure (DBP) (p < 0.001) on follow-up; and non-remission following induction therapy (p < 0.001). The 5-, 10- and 15-year renal survival rates in our patients were 63, 52 and 52 %, respectively. Hypertension at onset of LN (p = 0.037), nephrotic-range proteinuria (p = 0.033), eGFR < 60 ml/min/1.73 m(2) (p = 0.013) and lack of remission following induction therapy (p < 0.001) were all associated with development of end-stage renal disease (ESRD). Elevated SBP on follow-up (95 % CI 1.03-1.34, p = 0.017) was the only factor associated with composite end point while failure to achieve remission following induction therapy was the only factor associated with ESRD on multivariate analysis. Thirty-five (53 %) patients developed complications with persistent leukopenia, gastritis, sepsis, tuberculosis (TB) and herpes zoster being the leading complications. Ovarian failure occurred in 4 (11 %) patients.
The 5-, 10 and 15-year event-free survival rates were 54, 34 and 27 % and failure to achieve remission following induction therapy predicted poor renal survival on multivariate analysis.
报告南非增生性狼疮肾炎(PLN)患者的长期预后和并发症情况。
对 1995 年 1 月至 2009 年 12 月期间在我们中心接受治疗的 66 例经活检证实的 PLN(58 例弥漫性增生性 LN[IV 级]和 8 例局灶性增生性 LN[III 级])患者进行回顾性分析。
33 例(50%)患者达到血清肌酐翻倍、终末期肾病(ESRD)或死亡的复合终点。5、10 和 15 年无累积事件生存率分别为 54%、34%和 27%。与复合终点相关的变量包括 SLE 和 LN 的同时诊断(p=0.048);起病时血清肌酐升高(p=0.009);随访时收缩压(SBP)升高(p<0.001)和舒张压(DBP)升高(p<0.001);以及诱导治疗后未缓解(p<0.001)。我们患者的 5、10 和 15 年肾脏生存率分别为 63%、52%和 52%。LN 起病时高血压(p=0.037)、肾病范围蛋白尿(p=0.033)、eGFR<60 ml/min/1.73 m²(p=0.013)和诱导治疗后未缓解(p<0.001)均与 ESRD 的发生有关。随访时 SBP 升高(95%CI 1.03-1.34,p=0.017)是与复合终点相关的唯一因素,而诱导治疗后未缓解是与 ESRD 相关的唯一因素。35 例(53%)患者出现并发症,持续性白细胞减少、胃炎、败血症、结核病(TB)和带状疱疹是主要并发症。4 例(11%)患者发生卵巢功能衰竭。
5、10 和 15 年无事件生存率分别为 54%、34%和 27%,而诱导治疗后未缓解预测多变量分析中的肾脏预后不良。